A six-word narrative about living with blood cancer from patients in our LLS Community Stay strong and keep moving forward.Find the positive in every day.Be your own best patient advocate.Changed my life for the better.Accept, learn and focus on present.Learning to live a different life.Sudden and life changing-be positive.Waiting, worrying, anxiousness/ happy I'm alive!Embrace a new normal each day.5 years, 41 infusions, constant fatigue.Patience, positive attitude, hope and faith.Test to test, I will survive!Treatment, fatigue, treatment, fatigue and survival.Love life, live better every day.I don't look back only forward.So far, so good, live life.Meditation, mindfulness, wellness, faith, nutrition and optimism.Finding the joy while living with uncertainty.Watch, wait, treat, regroup, rest, re-energize.Blessed to be doing so well!Eye opening needed learning and healing.Feel great: uncertain travel plans annoying.Renewed faith, meditation, diet, mindfulness, gratitude.Watchful waiting can be watchful worrying.Scary, expensive, grateful, blessings, hope, faith.Thank god for stem cell transplants!Do not know what to expect.Extraordinarily grateful, I love my life.Diagnosed; frightened; tested; treating; waiting; hoping.I'm more generous, impatient less often.Embrace your treatment day after day.Live today, accept tomorrow, forget yesterday.Strength you never realized you had.Challenging to our hearts and minds.Life is what we make it.Live life in a
This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the safety, tolerability, and potential benefits of VERVE-101, the company's timing and ability to enroll patients in its ongoing heart-1 trial, the timing of initiation of a clinical trial of VERVE-102, the Company's research and development plans, and the potential advantages and therapeutic potential of the Company's programs, including VERVE-101 and VERVE-102.All statements, other than statements of historical facts, contained in this presentation, including statements regarding the Company's strategy, future operations, future financial position, prospects, plans and objectives of management, are forward-looking statements.The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements.These risks and uncertainties include, but are not limited to, risks associated with the Company's limited operating history; the Company's ability to timely submit and receive approvals of regulatory applications for its product candidates; advance its product candidates in clinical trials; initiate, enroll and complete its ongoing and future clinical trials on the timeline expected or at all; correctly estimate the potential patient population and/or market for the Company's product candidates; replicate in clinical trials positive results found in preclinical studies and/or earlier-stage clinical trials of VERVE-101, VERVE-102 and VERVE-201; advance the development of its product candidates under the timelines it anticipates in current and future clinical trials; obtain, maintain or protect intellectual property rights related to its product candidates; manage expenses; and raise the substantial additional capital needed to achieve its business objectives.For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the "Risk Factors" section, as well as discussions of potential risks, uncertainties and other important factors, in the Company's most recent filings with the Securities and Exchange Commission and in other filings that the Company makes with the Securities and Exchange Commission in the future.In addition, the forward-looking statements included in this presentation represent the Company's views as of the date hereof and should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.
Guidelines published in 2016 provide a revised definition of sepsis: life-threatening organ dysfunction caused by a dysregulated host response to infection. The guidelines define septic shock as sepsis with circulatory, cellular, and metabolic dysfunction that is associated with a higher risk of mortality. The measurement of serum lactate has been incorporated into the latest septic shock definition. The guidelines recommend the Sequential Organ Failure Assessment (original and quick versions) as an important tool for early diagnosis. Respiratory, gastrointestinal, genitourinary, and skin and soft tissue infections are the most common sources of sepsis. Pneumonia is the most common cause of sepsis. Although many patients with sepsis have fever, the clinical manifestation can be subtle, particularly in older patients and those who are immunocompromised. Initial evaluation of patients with suspected sepsis includes basic laboratory tests, cultures, imaging studies as indicated, and sepsis biomarkers such as procalcitonin and lactate levels. Fluid resuscitation is the priority in early management, including administering an intravenous crystalloid at 30 mL per kg within the first three hours. Antimicrobial therapy should also be initiated early. Most research indicates that antimicrobial therapy should be started within three hours of presentation. The latest guidelines recommend starting antimicrobials within one hour, but this is controversial. Vasopressor therapy is indicated if hypotension persists despite fluid administration. Future trials of sepsis management are focusing on improving long-term rates of readmission and death, physical disability, cognitive impairment, and quality of life.
Structure: e.g.how many emergency operating theatres are available 24 hours per day?◗ ◗ Process: e.g.what percentage of the components of the ventilator bundle are delivered reliably ◗ ◗Outcome: e.g.what is your hospital's 30 day mortality for ruptured aortic aneurysm?Much audit has been process based; many of the audits in the 2006 Edition assess adherence to process measures.Although we still have this emphasis, we would urge anaesthetists undertaking a process-based audit to always consider the question, how will this improve care for my patients?The NHS White Paper 'Equity and Excellence: Liberating the NHS' 12 demands a 'relentless focus on clinical outcomes'.It states that success will be measured, not through bureaucratic process targets, but against results that really matter to patients... such as survival rates.Darzi's NHS plan 'High Quality Care for all' 13 describes the NHS as 'safe, effective and personal', and therefore audit should evaluate care against one of these three domains.These principles are also the central focus of the key Scottish Health Policy 'The Quality Strategy' which is currently being implemented by three Ambition Delivery Groups for Safe, Effective and Person-Centred Care. 14 The Compendium is now in two sections.The first section is an updated version of the Audit Recipe Book.The second section includes some simple guides to basic improvement techniques, based mainly on the PDSA cycle developed by Associates in Improvement 15 and taught by the Institute for Healthcare Improvement. 16 Most of the UK safety and quality programmes such as the Safer Patients Initiative, the Lead in Patient Safety programme, the Scottish,Welsh and Southern safety programmes use this methodology, 6,7,8 and thereforeKnowing why or what you need to improve (audit will have provided this information). ◗ ◗Having a feedback mechanism to identify if improvement has happened (closing the audit loop). ◗ ◗Developing a change that will lead to improvement.◗ ◗ Testing a change before implementation, this may lead to multiple cycles of further change.◗ ◗ Knowing when you have an effective change that will lead to an improvement.Doctors have not traditionally been taught how to achieve change; and techniques widely used in industry, based on the work of Deming from which the Model for Improvement and most other improvement techniques derive, have only recently been introduced into healthcare. 22The quality improvement section provides some examples of the successful use of this technique to drive change.It is important to remember however, that improvement can result from learning from failure and so testing what works and learning what does not, is central to this methodology. The process of audit, quality improvement and the role of the Audit CompendiumAt its simplest level audit involves systematic collection and analysis of data to drive change in clinical practice.This may be manifest at several levels from the large national audit projects described, through structured hospital and departmental audit programmes, to individuals carrying out single projects.Perhaps the simplest form of cyclical examination of practice and change uses the PDSA (plan-do-study-act) methodology to drive small steps of change in practice at a very local level. 15,16 Whilst all these approaches are valid, the strengths and weaknesses of each have to be recognised.Large national audits may be comprehensive, well constructed and authoritative but locally may suffer from lack of ownership and an understanding of how to drive change identified by the audit, into widespread practice.The use of small stepwise changes in practice via application of PDSA cycles may be seen as a very basic level of audit.The principles of this methodology of change management are well described by the Institute of Health Care Improvement. 16 This process is increasingly recognised as a powerful and effective driver for change though its requirement for very local ownership and application may make widespread uniform applications difficult.However, the learning from small PDSA cycles can be accelerated by shared learning in collaborative working, an approach used with success in the national and regional patient safety programmes.In between these extremes lie single audit topics and the use of structured Departmental audit programmes.It is the intended place of this Audit Compendium to facilitate and strengthen the link between audit and quality improvement:Individual topics have been chosen to reflect key areas of practice, relating to quality of service, which are relevant to most departments.In this Edition we have attempted to prioritise clinical topics, though recognise also the value of organisational/departmental issues and their impact on overall service provision and quality of care. ◗ ◗Individual sections or themes may be used as a basis for developing a structured programme of audit across all sub-specialty areas of anaesthesia practice.Each section has been constructed by a theme editor who has recognised expertise in their area of practice.Individual topics have been chosen to reflect typical aspects of the theme and are written by authors with a proven track record.In developing such a structured programme, Departments may care to consider which of the topics are core, requiring regular investigation at specified time intervals, and those which are perhaps of more 'one-off ' or occasional relevance.
The transition from childhood to adulthood is a time of great change, both emotionally and physically, for any young person, but particularly for those living with a long-term condition. In England, more than 80,000 young people aged under 18 years are living with a life-threatening or life-limiting condition[1]. In addition, 23% of those aged 11–15 […]
Preventing disease and saving resources: the potential contribution of increasing breastfeeding rates in the UK
Ormskirk NHS Trust L iving with diabetes is not easy.It can be a daily struggle, both for children and young people (CYP) with the condition and those close to them.It is essential that CYP with diabetes are supported to manage their diabetes effectively to prevent the development of early complications as diabetes and emotional wellbeing form a two-way street: the condition can affect mental wellbeing, and mental health difficulties make managing the condition more challenging.
correction for 2020 data 1 Proportion based on the number of patients with non-positive NTM tests in the previous two data years 2 Proportion based on the number of patients with non-positive M.abscessus tests in the previous two data years
Medical advances offer the hope of bringing benefits to patients but also have the potential to do harm if not used appropriately.Knowing when and how to treat patients is particularly important in the prescribing of drugs as populations age and multi-morbidity becomes more prevalent.The challenge for clinicians is keeping up to date with new drugs as they come on the market and being aware of the interaction between them in patients being treated for a number of medical conditions.In an analysis of more than 300,000 patients, a Scottish study found that the mean number of drugs dispensed increased from 3.3 in 1995 to 4.4 in 2010.As the authors of this paper explain, this meant that the proportion of patients receiving 5 or more drugs increased from 12 to 22 per cent, and the proportion of patients receiving 10 or more drugs increased from 1.9 to 5.8 per cent.This matters because unless the drugs prescribed to patients are reviewed regularly by clinicians with up-to-date knowledge there is a risk that treatment may be ineffective at best and harmful at worst.A desire to increase awareness of the importance of polypharmacy prompted The King's Fund to commission this paper with the aim of bringing together what is known about this topic and to identify the implications for policy and practice.The Fund's interest derives from work on the care of people with long-term conditions and how this can be improved.Our brief to the authors was to review the evidence on polypharmacy and particularly to highlight how to optimise the contribution that medicines make to enabling informed patient choice and delivering desired outcomes for patients.viii
Four common pathological conditions are associated with vaginal discharge: bacterial vaginosis, aerobic vaginitis, candidosis, and the sexually transmitted infection, trichomoniasis.Chlamydial or gonococcal cervical infection may result in vaginal discharge.Vaginal discharge may be caused by a range of other physiological and pathological conditions including atrophic vaginitis, desquamative inflammatory vaginitis, cervicitis, and mucoid ectopy.Psychosexual problems may present with recurrent episodes of vaginal discharge and vulval burning.These need to be considered if tests for specific infections are negative.Many of the symptoms and signs are non-specific and a number of women may have other conditions such as vulval dermatoses or allergic and irritant reactions.
Early intervention is crucial for people with rheumatoid arthritis, because there is a window of opportunity in which to prevent joint damage and reduce the chance of subsequent deformity and vascular effects, such as myocardial infarction and cerebrovascular accident. Even when a clear diagnosis of rheumatoid arthritis has not been made, but there is definite evidence of an inflammatory arthritis, it is crucial that introduction of effective treatment is not delayed. Pharmacological treatments play a key role in managing both the early and the later stages of RA. The National Institute for Health and Clinical Excellence’s clinical guideline on RA outlines the current treatment approach. Not only is early use of disease-modifying antirheumatic drugs (DMARDs) encouraged, but combinations of DMARDs are advocated following diagnosis, alongside use of injected or oral steroids. There can often be a fine balance between achieving disease control (assessed using disease activity score — see Box 1, p162) and minimising side effects.
